Matthew T. Wiley - Net Worth and Insider Trading
Matthew T. Wiley Net Worth
The estimated net worth of Matthew T. Wiley is at least $193,785 dollars as of 2024-06-15. Matthew T. Wiley is the Chief Commercial Officer of Foamix Pharmaceuticals Ltd and owns about 63,440 shares of Foamix Pharmaceuticals Ltd (FOMX) stock worth over $189,686. Matthew T. Wiley is also the CHIEF COMMERCIAL OFFICER of BioXcel Therapeutics Inc and owns about 2,992 shares of BioXcel Therapeutics Inc (BTAI) stock worth over $4,099. Details can be seen in Matthew T. Wiley's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Matthew T. Wiley has not made any transactions after 2024-04-04 and currently still holds the listed stock(s).
Transaction Summary of Matthew T. Wiley
Matthew T. Wiley Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Matthew T. Wiley owns 3 companies in total, including VYNE Therapeutics Inc (VYNE) , Foamix Pharmaceuticals Ltd (FOMX) , and BioXcel Therapeutics Inc (BTAI) .
Click here to see the complete history of Matthew T. Wiley’s form 4 insider trades.
Insider Ownership Summary of Matthew T. Wiley
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| VYNE | VYNE Therapeutics Inc | 2020-03-09 | Chief Commercial Officer |
| FOMX | Foamix Pharmaceuticals Ltd | 2020-03-09 | Chief Commercial Officer |
| BTAI | BioXcel Therapeutics Inc | 2024-04-04 | CHIEF COMMERCIAL OFFICER |
Matthew T. Wiley Latest Holdings Summary
Matthew T. Wiley currently owns a total of 2 stocks. Among these stocks, Matthew T. Wiley owns 63,440 shares of Foamix Pharmaceuticals Ltd (FOMX) as of March 5, 2019, with a value of $189,686 and a weighting of 97.88%. Matthew T. Wiley also owns 2,992 shares of BioXcel Therapeutics Inc (BTAI) as of April 4, 2024, with a value of $4,099 and a weighting of 2.12%.
Latest Holdings of Matthew T. Wiley
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| FOMX | Foamix Pharmaceuticals Ltd | 2019-03-05 | 63,440 | 2.99 | 189,686 |
| BTAI | BioXcel Therapeutics Inc | 2024-04-04 | 2,992 | 1.37 | 4,099 |
Holding Weightings of Matthew T. Wiley
Matthew T. Wiley Form 4 Trading Tracker
According to the SEC Form 4 filings, Matthew T. Wiley has made a total of 0 transactions in Foamix Pharmaceuticals Ltd (FOMX) over the past 5 years. The most-recent trade in Foamix Pharmaceuticals Ltd is the acquisition of 13,440 shares on March 5, 2019, which cost Matthew T. Wiley around $50,534.
According to the SEC Form 4 filings, Matthew T. Wiley has made a total of 1 transactions in BioXcel Therapeutics Inc (BTAI) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in BioXcel Therapeutics Inc is the sale of 1,008 shares on April 4, 2024, which brought Matthew T. Wiley around $2,661.
Insider Trading History of Matthew T. Wiley
- 1
Matthew T. Wiley Trading Performance
GuruFocus tracks the stock performance after each of Matthew T. Wiley's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matthew T. Wiley is -33.59%. GuruFocus also compares Matthew T. Wiley's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matthew T. Wiley within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Matthew T. Wiley's insider trading performs compared to the benchmark.
Performance of Matthew T. Wiley
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 3.39 | | | | | |
| Relative Return to S&P 500(%) | -0.31 | | | | | |
Matthew T. Wiley Ownership Network
Matthew T. Wiley Owned Company Details
What does VYNE Therapeutics Inc do?
Who are the key executives at VYNE Therapeutics Inc?
Matthew T. Wiley is the Chief Commercial Officer of VYNE Therapeutics Inc. Other key executives at VYNE Therapeutics Inc include Chief Legal Officer and GC Mutya Harsch , 10 percent owner Perceptive Life Sciences Master Fund Ltd , and Interim CFO Tyler Zeronda .
VYNE Therapeutics Inc (VYNE) Insider Trades Summary
Over the past 18 months, Matthew T. Wiley made no insider transaction in VYNE Therapeutics Inc (VYNE). Other recent insider transactions involving VYNE Therapeutics Inc (VYNE) include a net purchase of 33,000 shares made by Patrick G Lepore , and a net purchase of 10,000 shares made by Mutya Harsch .
In summary, during the past 3 months, insiders sold 0 shares of VYNE Therapeutics Inc (VYNE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of VYNE Therapeutics Inc (VYNE) were sold and 43,000 shares were bought by its insiders, resulting in a net purchase of 43,000 shares.
VYNE Therapeutics Inc (VYNE)'s detailed insider trading history can be found in Insider Trading Tracker table.
VYNE Therapeutics Inc Insider Transactions
Matthew T. Wiley Mailing Address
Above is the net worth, insider trading, and ownership report for Matthew T. Wiley. You might contact Matthew T. Wiley via mailing address: C/o Foamix Pharmaceuticals Ltd., 2 Holtzman St, Weizmann Science Park, Rehovot L3 7670402.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
